In silico Design, Synthesis and Biological Evaluation of Novel Thieno[3,2‐d]pyrimidine Derivatives for Cancer Therapy – A Preliminary Study on the Inhibitory Potential towards ATR Kinase Domain and PIKK Family

Abstract

Continuing our studies in the field of new heterocyclic compounds with biological interest, herein we report the synthesis and anticancer activity of new N‐ and S‐substituted derivatives of tetracyclic pyrido[3',2':4,5]thieno[3,2‐d]pyrimidines. In this regard, starting from the thieno[2,3‐b]pyridine‐2‐carboxylates, the corresponding 8(9)‐aminopyrido[3',2':4,5]thieno[3,2‐d]pyrimidin‐7(8)‐ones, as well as chloro derivatives were obtained. Based on the latter, amino, hydrazino and S‐alkyl derivatives of pyrido[3',2':4,5]thieno[3,2‐d]pyrimidines were synthesized subsequently. The current study focuses on identifying the potential of thieno[3,2‐d]pyrimidine derivatives primarily towards ATR kinase inhibition, through computational predictions, followed by synthesis and cancer cell viability studies, along with an aim to develop the core as PIKK inhibitors for cancer therapy.